Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
ALS, Amyotrophic Lateral Sclerosis
A Trial of Tocilizumab in ALS Subjects
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
- Trial name
- TCZALS-001 (NCT02469896)
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barrow Neurological Institute
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps…
- Conditions
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- NCT00324454
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis, Respiratory Insufficiency
Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation
ALS is is characterized by a progressive degeneration of motor neurons, leading to progressive weakness of muscles, including respiratory muscles, the diaphragm.
- Trial name
- RespiStimALS (NCT01583088)
- Testing
- phenique nerve stimulation NeurX™ (Synapse Biomedical)
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Neuromuscular Magnetic Stimulation in ALS Patients
Aim of the study is to verify whether neuromuscular magnetic stimulation can improve muscle function in spinal-onset Amyotrophic Lateral Sclerosis (ALS) patients.
- Trial name
- NMS-ALS (NCT03618966)
- Testing
- Neuromuscular magnetic stimulation (NMMS)
- Volunteers
- 22 people
- Sponsor
- University of Roma La Sapienza
Amyotrophic Lateral Sclerosis
Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis
The aim of this study is to investigate the usability of the 1 Minute Sit to Stand Test (1 MSTS) in evaluating physical capacity and effort-related desaturation in individuals with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT05151211
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Amyotrophic Lateral Sclerosis
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT01511029
- Testing
- Dexpramipexole, Moxifloxacin
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24…
- Trial name
- NCT00330681
- Testing
- MCI-186
- Volunteers
- 206 people
- Sponsor
- Shionogi
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study…
- Trial name
- NCT07571200
- Testing
- LY4256984
- Where
- 11 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Sialorrhea, Amyotrophic Lateral Sclerosis
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
Evaluation of the decrease of the secretion of saliva in patients with amyotrophic lateral sclerosis by a local ultrasound-guided bilateral injection of botulinum toxin type A in parotids and submandibular glands.
- Trial name
- ALS-TOX (NCT01551940)
- Testing
- Botox injection
- Where
- 13 sites in France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Amyotrophic Lateral Sclerosis
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study.
- Trial name
- ALSTAR OL (NCT00982150)
- Testing
- Talampanel
- Volunteers
- 446 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Amyotrophic Lateral Sclerosis
Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves not only motor structures, as was previously thought, but also brain areas dealing with cognition as well as parts of the limbic system.
- Trial name
- SLAMEM (NCT01530438)
- Testing
- MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
- Where
- 2 sites in France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks.
- Trial name
- NCT03508453
- Testing
- IC14
- Where
- Australia
- Sponsor
- Implicit Bioscience
Amyotrophic Lateral Sclerosis
Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
A multi-center registration study of natural history and clinical characteristics of ALS in mainland China
- Trial name
- ChALSR (NCT04328675)
- Where
- China
- Volunteers
- 4,752 people
- Sponsor
- Peking University Third Hospital
ALS
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point…
- Trial name
- NCT05151471
- Testing
- MT-1186
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 202 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Intermediate-Sized Expanded Access Study
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
- Trial name
- NCT05597436
- Testing
- Trehalose
- Where
- 21 sites in United States
- Sponsor
- Seelos Therapeutics, Inc.
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid
Cerebrospinal Fluid Repository
The purpose of a CSF repository is to collect samples of spinal fluid from controls and patients with neurologic disorders including but not exclusively ALS, Dementia, CRPS, neuropathies, and other neuromuscular diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- CSF (NCT00714636)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
- Trial name
- CL211 (NCT00931944)
- Testing
- KNS-760704
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
ALS and Airway Clearance (ALSAC) Therapy
Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE.
- Trial name
- ALSAC (NCT04947436)
- Testing
- High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Tremor, Involuntary Movements
Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen
Hyperkinetic movement disorders in patients with diseases of motor neurons will be studied. Patients with spinal muscular atrophy (SMA) and motor neuron disease patients will be studied.
- Conditions
- Tremor, Involuntary Movements, SMA, MND (Motor Neurone DIsease)
- Trial name
- NCT04825119
- Testing
- Nusinersen
- Where
- Slovenia
- Volunteers
- 110 people
- Sponsor
- University Medical Centre Ljubljana